MAYNE PHARMA REPORTS 1HFY15 RESULT 26 February 2015, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to release its consolidated results for the half-year ended 31 December 2014. Commenting on the result, Mayne Pharma’s CEO, Mr Scott Richards said, “As clearly signalled at our November AGM, our first half was materially impacted by the lack of contribution from sales of US DoryxTM tablets to Actavis, a key product which is now controlled by the Company following the successful completion of the Doryx™ acquisition1 on 24 February 2015. We are very excited about building this franchise under our ownership and delivering long-term value to Mayne Pharma. Following a transition period of approximately two months, Mayne Pharma will launch this product through its new US Specialty Brands Division and control the entire supply chain from manufacture, packaging and distribution, through to sales and marketing. Excluding sales of US Doryx™, the rest of the business grew 6% on the prior comparable period (pcp), driven by the key direct US generic products, our contract services business and Lozanoc™, our improved formulation of itraconazole.” Question Follow the link below: http://www.maynepharma.com/investor-relations/results-and-reports Introductory page identifying the company you have researched and a couple of sentences about the company, ( 500 words).